AI Holders Summary · Q1 2026

SYK Q1 2026 institutional ownership is a $91.5B book across 2,222 holders. BlackRock is the largest holder at $9.1B (27.6M shares, -4.2%, -$578M). Vanguard Capital Management is second at $7.4B (22.4M shares, NEW after three-way split). Greenleaf Trust is third at $5.2B (15.9M shares, -10.0%, -$585M) -- the largest seller. JPMorgan is fourth at $5.1B (15.6M shares, +27.9%, +$818M) -- the largest buyer. State Street is fifth at $5.1B (15.3M shares, -2.8%, -$318M). Vanguard Portfolio Management $2.7B (NEW); Vanguard Fiduciary Trust $641M (NEW). Wellington Management $2.7B (+37.5%, +$387M). Geode Capital $2.5B (+1.7%). FMR/Fidelity $777M (-25.9%, -$271M). AllianceBernstein $2.1B (-8.2%, -$138M). Morgan Stanley $2.1B (+1.7%, shares up but value -$127M). Capital Research Global $1.8B (-8.4%, -$253M). Bank of America $1.4B (-13.1%, -$204M). Northern Trust $1.1B (-2.4%, -$91M). MassFinancial $877M (not in top-20). Goldman Sachs $889M (+22.7%, +$124M). UBS AM $726M (+17.8%, +$69M). UBS Group $554M (+1.0%, +$6M). Legal & General $780M (+1.7%, shares up but value -$51M). RBC $1.1B (+5.1%, value declined). BNY Mellon $1.3B (-9.9%, -$217M). Franklin Resources $915M (-20.3%, -$209M). Fundsmith $1.0B (-30.2%, -$290M). First Western Trust Bank $992M (-13.2%, -$151M). New positions: Vanguard three-way. Sellers: Greenleaf -$585M, BlackRock -$578M, State Street -$318M, AllianceBernstein -$138M, Capital Research -$253M, Fundsmith -$290M, Fidelity -$271M, Franklin -$209M, Bank of America -$204M, BNY Mellon -$217M, First Western -$151M. Buyers: JPMorgan +$818M, Wellington +$387M, Goldman +$124M, UBS AM +$69M, UBS Group +$6M. The 75.50 whaleScore reflects AUM. Smart-money-signal read: SYK Q1 2026 flows are net-bullish despite notable sellers. JPMorgan's +$818M (+27.9%) is the largest buy across the entire dataset for this quarter. Wellington +$387M and Goldman +$124M reinforce. The seller cohort is large but composed of managers reducing existing large positions rather than uniformly exiting. The defining signal: JPMorgan's aggressive new build in medtech. Net read: net-bullish on Stryker.

Top holders